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Abstract
Background: A genome-wide association study (GWAS), which assessed multiple ethnicities,
reported an association between single nucleotide polymorphisms in the 8q24 region and
colorectal cancer risk. Although the association with the identified loci was strong, information on
its impact in combination with lifestyle factors is limited.
Methods: We conducted a case-control study in 481 patients with colorectal cancer (CRC) and
962 sex-age matched non-cancer controls. Data on lifestyle factors, including diet, were obtained
by self-administered questionnaire. Two 8q24 loci, rs6983267 and rs10090154, were assessed by
the TaqMan method. Associations were then assessed by multivariate logistic regression models
that considered potential confounders.
Results: We found an increased risk of CRC with rs6983267 but not with rs10090154. An allelic OR
was 1.22 (1.04-1.44, p for trend = 0.014), which remained significant after adjustment for confounders
(OR = 1.25). No statistically significant interaction with potential confounding factors was observed.
Conclusion: The polymorphism rs6983267 showed a significant association with CRC in a Japanese
population. Further investigation of the biological mechanism of this association is warranted.
Background
Colorectal cancer (CRC) remains major cancer worldwide
[1]. Although numerous epidemiological and biological-
studieshaverevealedrisk/protectivefactorsforCRC,present
knowledge is still insufficient to allow the disease to be
overcome, and the struggle to elucidate mechanisms is
ongoing.
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Open AccessRecently, several a number of genome-wide association
studies (GWAS) have revealed an association between
variants on chromosome 8q24 and several sites of
cancer, including CRC [2-11]. Each study showed that
rs6983267 resides in 128.47-128.54 MB on Chromo-
some 8, denoted as ‘region 3,’ [7] and consistently
associated with CRC [6,9,12]. This association was
confirmed in a subsequent large-scale replication study
in Caucasians [13-18]. Most of these CRC GWASs were
conducted in Caucasian populations, however, and the
data available for Asian populations is limited especially
about possible gene-environment interaction [6,19].
The aim of the present case-control study was to clarify the
impact of rs6983267 on CRC risk in a Japanese population.
In addition, we explored the gene-environmental interac-
tion between potential confounders and rs6983267.
Methods
Subjects
Cases were 481 patients who were histologically diagnosed
with CRC (245 with colon cancer, 231 with rectum cancer)
between January 2001 and November 2005 at Aichi Cancer
Center Hospital (ACCH) and who had no prior history of
cancer. Controls were first-visit outpatients at ACCH during
thesameperiodswhowereconfirmedtohavenocancerora
prior history of neoplasm. Controls were randomly selected
and matched for sex and age (± 4 years) with a 1:2 case-
control ratio (n = 962). The subjects were selected from the
database of the Hospital-based Epidemiologic Research
Program at Aichi Cancer Center (HERPACC). The frame-
work of HERPACC has been described elsewhere [20,21].
Briefly, all outpatients aged 20-79 years were asked at first
visit to fill out a questionnaire regarding their lifestyle and
provided 7 ml of blood. A trained interviewer checked the
completion of each questionnaire. Approximately 95% of
eligible subjects completed the questionnaire and 55%
providedbloodsamples.Some30%offirst-visitoutpatients
were diagnosed at ACCH as having cancer. Under the
assumption that the non-cancer population within HER-
PACC will visit ACCH if they develop cancer in the future,
we defined non-cancer first-visit outpatients as those from
among whom such cases may arise. Our previous study
confirmed that the lifestyle patterns of first-visit outpatients
matched the profile of a group randomly selected from the
general population of Nagoya City, conferring external
validity on the study [22]. Written informed consent was
obtained from all subjects and the ethics committee of ACC
approved the study.
Determination of the 8q24 loci genotype
DNA of each subject was extracted from the buffy coat
fraction with a Blood Mini Kit (Qiagen K.K., Tokyo,
Japan) and assessed using the polymerase chain reaction
(PCR) TaqMan method [23] with the 7500 Fast Real-
time PCR system (Applied Biosystems, Foster City, CA,
USA). The probes used were specifically designed for
rs6983267 and rs10090154 in 8q24. rs10090154 in
the 8q24 ‘region 1’ [7] was chosen because it showed a
significant association for a Japanese population in
Hawaii [6]. The quality of genotyping was assessed by
duplicate analysis of 5% of random samples, with an
agreement rate of 100%.
Exposure data
Cumulative smoking dose was evaluated as pack-years, the
productofthenumberofpacksconsumedperdayandyears
of smoking. Smoking habit was classified into the three
categories of never, pack-years < 20 (low-moderate) and
≥ 20 packyears(heavy).Consumptionoftypesofalcoholic
beverages (Japanese sake,b e e r ,shochu,w h i s k e ya n dw i n e )
per occasion was determined with reference to the average
number of drinks per day, which was then converted into a
Japanese sake (rice wine) equivalent (one unit sake = 23 g
ethanol) [24]. Daily ethanol consumption was estimated as
the product of the frequency of alcohol beverage and
average ethanol consumption occasion, and drinking habit
was classified into the four categories of non-drinker, low
(< 5 g/day), moderate (< 23 g/day) and heavy (≥ 23 g/day).
Consumption of folate was determined using a semi-
quantitative food frequency questionnaire (SQFFQ) as
described in detail elsewhere [25]. Briefly, the SQFFQ
consisted of 47 single food items with frequencies in the
eight categories of never or seldom, 1-3 times/month,
1-2 times/week, 3-4 times/week, 5-6 times/week, once/day,
twice/day, and 3+ times/day. Average daily intake of
nutrients was estimated by multiplying the food intake (in
grams) orservingsize by thenutrientcontent per100grams
of food as listed in the Standard Tables of Food Composi-
tion in Japan, 5
th edition. Consumption of supplemental
folate was not considered in total consumption because the
questionnaire for multi-vitamins was not quantitative.
Energy-adjusted intake of nutrients was calculated by the
residual method [26]. The SQFFQ was validated by
reference to a 3-day weighted dietary record as a standard,
which showed the reproducibility and validity to be
acceptable [27,28]. The de-attenuated correlation coeffi-
cientsforenergy-adjustedintakesoffolatewere0.36inmen
and 0.38 in women. Body mass index (BMI) was calculated
as the self-reported weight (kilograms) divided by the
square of self-reported height (meters). A family history of
CRC in first-degree relatives was based on self-reporting, as
described elsewhere [29]. The questionnaire also covered
the regularity of physical exercise: subjects were asked to
report the frequency and intensity of recreational exercise,
with average daily exercise hours in any intensity calculated
and categorized into the three levels of none, and < 0.5 and
≥ 0.5 hours/day.
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Odds ratios (ORs) and 95% confidence intervals (CIs)
for assessment of the impact of each 8q24 locus,
included in the model as an ordinal score (1 to 3),
were calculated using multivariable conditional logistic
regression models. We explored two models: model 1
was a crude model; model 2 included age and sex plus
potential confounders as indicator variables. Confoun-
ders considered in model 2 were smoking status (never,
former, current moderate, and heavy), drinking habit
(non, low, moderate, and heavy), folate consumption by
tertile (T1-3), BMI (< 22.5, 22.5 - 24.9, 25.0-27.4 and
≥ 27.5 kg/m
2), family history of colorectal cancer (yes or
no), and regular exercise (none, < 0.5 hour/day, and
≥ 0.5 hour/day). Interactions between rs6983267
assuming linear effect of allele and potential confounders
similarly assuming linear effect were assessed in multi-
variable unconditional logistic regression models to avoid
the dropping of subjects in conditional logistic regression
models. To assess possible discrepancies between expected
and observed haplotypes, accordance with the Hardy-
Weinberg equilibrium (HWE) was checked for controls
with the c
2 test. Statistical analyses were performed using
STATA version 10 (Stata, College Station, TX), with P-values
< 0.05 considered statistically significant.
Results
Table 1 shows baseline characteristics of the 481 CRC
cases, with an average age of 60 years, and the 962
Table 1: Characteristics of cases and controls
Variables Cases Controls p-values
Total 481 962
Sex 1.00
Male 300 62.4% 600 62.4%
Female 181 37.6% 362 37.6%
Age (years) 0.803
< 40 20 4.2% 39 4.1%
40-49 50 10.4% 105 10.9%
50-59 169 35.1% 328 34.1%
60-69 164 34.1% 353 36.7%
70- 78 16.2% 137 14.2%
Mean age (SD) 60 (10.2) 60 (9.86)
Site of Cancer
Colon 245 50.9%
Rectum 236 49.1%
Smoking 0.102
None 215 44.7% 493 51.3%
Low-moderate (< 20 pack-years) 59 12.3% 116 12.1%
Heavy (≥ 20 pack-years) 203 42.2% 345 35.9%
Unknown 4 0.8% 8 0.8%
Drinking 0.695
None 190 39.5% 383 39.8%
Low (< 5 g ethanl/day) 64 13.3% 125 13.0%
Moderate (5≤ and < 23 g ethanol/day) 85 17.7% 196 20.4%
High (≥ 23 g ethanol/day) 135 28.1% 243 25.3%
Unknown 7 1.5% 15 1.6%
Daily folate consumption 0.857
T1 (≤ 262.0 μg/day) 153 31.8% 286 29.7%
T2 (≤ 346.6 μg/day) 158 32.9% 318 33.1%
T3 (> 346.6 μg/day) 162 33.7% 341 35.5%
Unknown 8 1.7% 17 1.8%
Body-Mass Index (BMI) kg/m
2 0.923
< 22.5 206 42.8% 397 41.3%
22.5 ≤ and < 25 157 32.6% 314 32.6%
25 ≤ and < 27.5 73 15.2% 162 16.8%
≥ 27.5 41 8.5% 79 8.2%
Unknown 4 0.8% 10 1.0%
Family history of colorectal cancer in the first degree relatives 0.014
No 453 94.2% 932 96.9%
Yes 28 5.8% 30 3.1%
Average recreational exercise 0.329
None 192 39.9% 349 36.3%
< 0.5 hour/day 194 40.3% 398 41.4%
0.5 ≤ hour/day 95 19.8% 215 22.4%
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a first-degree relative, potential confounders showed no
clear difference between cases and controls. A family
history of CRC was significantly more frequent among
CRC cases.
Genotype distributions for 8q24 rs6983267 and
rs10090154 are shown in Table 2. Among controls, both
genotypes were accordant with the HWE. The minor allele
frequency for rs6983267 was 0.338 (G-allele). The age-
and sex-adjusted in the allelic model showed an OR of
1.22 (1.04-1.44, p = 0.0144) and the confounder-adjusted
model an OR of 1.25 (1.06-1.48, p = 0.0071). Genotypic
model showed a significant association only with
rs6983267 GG genotype (OR = 1.64, 1.15-2.35, p =
0.0063). In contrast, rs10090154 showed no association
with CRC risk. Table 3 shows stratified analyses conducted
to explore possible interactions between potential con-
founders although point estimates for ORs were not static;
no significant interactions were seen between the factors
examined and rs6983267. The lack of association in those
with a positive family history was of interest vis a vis the
significant association in those without it, albeit that the
number of subjects with a family history was limited.
Discussion
In this study, we found that the G allele in rs6983267
was associated with a significantly increased risk of CRC
in a Japanese population. This finding is consistent with
those from previous GWASs [6,9,11] and a pooled
analysis [12], as reviewed in Table 4, which reported the
consistency of this association with CRC and colorectal
adenoma in populations with European ancestry. The
only previous study of rs6983267 in a population with
Asian ethnicity (Japanese-American) was that by Haiman
et al [6], and to our knowledge the present study is the
f i r s ti n d i c a t i o ni nJ a p a n e s el i v i n gi nJ a p a n .T e n e s ae ta l .
reported significant association with rs7014346 in 8q24,
which is in high linkage disequilibrium with rs6983267,
in Japanese population [19], supporting significant
association between the rs6983267 in CRC in Japanese.
Recent advances in genetic analysis have enabled a
comprehensive approach to identifying disease suscept-
ibility loci. The consistency of findings in this and the
previous studies warrants the usefulness of the GWAS
approach across ethnicities. We also evaluated potential
interactions between common background factors and
rs6983267, but found no significant interaction between
them. Berndt et al. also reported a lack of interaction
between rs6983267 and age, sex, smoking, family history
of CRC and cancer site [12]. The consistency of this
finding indicates that rs6983267 is associated with CRC
risk independently of common risk factors.
Rs6983267 was originally identified using a non-
hypothesis-based approach, and evidence has suggested
a possible biological mechanism behind this observed
association. The rs6983267 polymorphism resides 15 kb
upstream of a processed pseudogene (POU5F1P1)o ft h e
POU-domain factor gene, POU5F1, which encodes
transcription factor OCT4, with 97.5% shared identity
[30]. OCT4, a transcript of POU5F1, plays a role in
maintaining stem cell pluripotency, self-renewal and
chromatin structure in stem cells [31], and promotes
tumor growth in a dose-dependent manner [32].
A conserved POU5F1-binding site I at the 5’ promoter
Table 2: Genotypes distribution of 8q24 polymorphisms and odds ratios for the minor alleles and genotypes
Allelic model Genotype model
Model 1 *1 Model 2 *2 Heterozygote Minor homozygote
8q24 locus Genotype OR 95% CI p-value OR
a 95% CI p-value OR
a 95% CI p-value OR
a 95% CI p-value
rs6983267 (Minor allele: G, MAF*1 in controls = 0.338)
TT TG GG UK*4
case/
control
181/
418
222/
436
73/107 3/1 1.22 1.04-1.44 0.0144 1.25 1.06-1.48 0.0071 1.19 0.93-1.52 0.1665 1.64 1.15-2.35 0.0063
rs10090154 (Minor allele: T, MAF in controls = 0.153)
CC CT TT UK
case/
control
355/
689
112/
247
11/23 3/3 0.90 0.72-1.12 0.3443 0.87 0.69-1.09 0.2140 0.83 0.63-1.08 0.1690 0.90 0.43-1.89 0.7854
*1 Crude conditional logistic regression model.
*2 Adjusted for age as continuous variable, drinking (non, low, moderate, heavy, and unknown), smoking (non, moderate, heavy, unknwon),
BMI (< 22.5, < 25, < 27.5, 27.5-, unknown), folate in tertile (T1, T2, T3, and unknown), total energy intake, family history of colorectal cancer, average
recreational exercise (none, < 0.5 hour/day, 0.5-hour/day) in conditional logisitic regression.
*3 MAF indicates minor allele frequency.
*4 UK indicates the subjects whose genotyping was unsuccessful.
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reported [33]. Tomlinson et al. reported the expression
of either POU5F1 or POU5F1P1 in cell lines and primary
CRCs [9], while Suo et al. similarly reported the
expression of these genes in cancer cell lines and cancer
tissues [30]. Given that OCT4 pseudogenes in mice are
reported to mediate stem cell regulatory function [34], it
is possible to hypothesize that OCT4 pseudogenes,
including POU5F1P1, might play a role in stem cell
proliferation. However, no difference in expression
according to rs6983267 status was observed [9]. Berndt
discussed the potential contribution of MYC,w h i c hi s
located > 300 KB distant to rs6983267[12]. Recently,
Pomerantz et al. reported rs6983267 displays a differ-
ence in binding of transcription factor 7-like 2 (TCF7L2)
leading to a different physical interaction with MYC [35];
however, Tuupanen et al. failed to find clear association
between rs6983267 genotype and MYC expression.
There still remains controversy between MYC and
rs6983267 requiring further studies. Moreover, Tuupa-
nen et al. reported rs6983267 affects a binding site for
the Wnt-regulated transcription factor (TCF4), with the
risk allele G showing stronger binding in vivo and in vitro.
Overall, these findings indicate that the possible
Table 3: Stratified analysis according to potential confounding factors for 8q24 rs6983267 genotype
rs6983267 allelic model
Model 1*1 Model*2
Exposure Number of
controls with
each genotype
(TT/TG/GG)
Number of
cases with
each genotype
(TT/TG/GG)
OR*1 95% CI p-value OR 95% CI p-value Interaction
P
Sex 0.181
Male 122/133/43 259/270/70 1.11 0.91-1.37 0.295 1.14 0.93-1.41 0.212
Female 61/89/30 159/166/37 1.44 1.10-1.88 0.007 1.34 1.01-1.78 0.040
Smoking 0.401
None 73/106/35 206/232/55 1.34 1.05-1.70 0.018 1.29 1.01-1.65 0.042
Low-moderate
(< 20 pack-years)
19/31/9 52/52/12 1.51 0.93-2.43 0.094 1.49 0.89-2.49 0.130
Heavy (≥ 20 pack-years) 88/84/29 158/147/39 1.11 0.86-1.43 0.423 1.12 0.86-1.44 0.407
Drinking 0.437
None 69/92/30 166/179/38 1.36 1.04-1.76 0.023 1.35 1.03-1.77 0.028
Low (< 5 g ethanl/day) 23/29/12 51/58/16 1.25 0.81-1.93 0.308 1.44 0.91-2.28 0.124
Moderate (5≤ and
<2 3ge t h a n o l / d a y )
34/41/9 85/83/27 0.98 0.67-1.43 0.918 0.99 0.67-1.46 0.941
High (≥ 23 g ethanol/day) 55/59/19 112/108/23 1.22 0.89-1.67 0.217 1.22 0.88-1.69 0.231
Daily folate consumption 0.694
T1 (≤ 262.0 μg/day) 54/73/25 112/137/37 1.14 0.85-1.53 0.375 1.22 0.90-1.66 0.197
T2 (≤ 346.6 μg/day) 59/75/22 104/141/36 1.21 0.91-1.61 0.191 1.25 0.93-1.67 0.141
T3 (> 346.6 μg/day) 66/72/24 157/152/32 1.24 0.94-1.64 0.135 1.30 0.97-1.73 0.080
Body-Mass Index
(BMI) kg/m
2
0.678
< 22.5 73/100/32 177/176/44 1.34 1.05-1.72 0.020 1.43 1.10-1.85 0.007
22.5 ≤ and < 25 69/69/19 128/148/37 0.93 0.70-1.25 0.663 0.93 0.69-1.25 0.637
25 ≤ and < 27.5 23/34/16 74/69/19 1.58 1.06-2.36 0.024 1.67 1.09-2.55 0.018
≥ 27.5 18/17/5 31/41/7 0.98 0.54-1.79 0.944 1.06 0.54-2.10 0.863
Family history of colorectal
cancer
in the first degree relatives
0.765
No 169/212/69 404/422/105 1.24 1.05-1.46 0.011 1.26 1.06-1.48 0.008
Yes 14/10/4 14/14/2 1.09 0.50-2.38 0.833 0.84 0.29-2.43 0.741
Average recreational exercise 0.109
None 77/90/24 161/140/48 1.10 0.85-1.42 0.462 1.13 0.87-1.47 0.356
< 0.5 hour/day 73/89/31 158/199/40 1.20 0.93-1.56 0.163 1.20 0.92-1.57 0.174
0.5 ≤ hour/day 33/43/18 99/97/19 1.59 1.11-2.28 0.012 1.70 1.15-2.50 0.008
*1 Odds ratios were adjusted for age and sex in unconditional logistic regression models. Conditional logistic models were not applied because
keeping matching in stratficiation gave unstabel estimation.
*2 Odds ratio adjusted for age, sex and all variables in this examination except variable used for stratification.
*3 Interaction term between rs6983267 genotype in score and stratifiying factor in socre was added in model 2.
*4 Subjects were exlucded from analysis because of lack of information, smoking (4 cases and 8 controls), drinking (7 cases and 15 controls), folate
(8 cases and 17 controls), and BMI (3 cases and 10 controls).
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polymorphism on CRC carcinogenesis requires further
study.
We did not observe any association with rs10090154
(OR = 0.90) on the contrary to the results from Multi-
ethnic cohort study [6]. The point estimate for minor
allele in the previous study was 1.41 (95%CI: 1.14-1.75).
Following case-control study for Japanese American in
Hawaii showed lack of association (OR = 1.07, 95%CI:
0.78-1.48)[6]. Inconsistency across studies might come
from the finding in the original GWAS was by chance
although threshold in statistical significance was high
enough. Or, statistical power in following studies
including ours was not good enough. By all means,
more evidence is needed to clarify significance of the
locus.
Several potential limitations of the present study require
consideration. First, use of hospital-based control in this
study for potential cause of selection bias. We used non-
cancer patients at our hospital as controls, given the
likelihood that our cases arose within this population
base. Moreover, we previously showed that individuals
selected randomly from our control population were
similar to the general population in terms of baseline
characteristics [22]. Given the similarity in minor allele
frequency between our controls and that in the HapMap
database for Japanese, it is reasonable to assume the
external validity of our study results to the general
Table 4: Review of results of 8q24 rs6983267 for colorectal cancer in allelic model
Author Year Case/Control Country Study subjects Per allele OR
(95%CI)
Adjustment
Haiman et al. 2007 1,807/5,511 USA Pooled 1.25 (1.12-1.38) Sex
217/1,049 African American 1.37 (0.98-1.91) Sex
381/1,197 Japanese American 1.13 (0.96-1.34) Sex
61/347 Native Hawaiian 1.59 (1.02-2.47) Sex
251/1,007 Latinos 1.26 (1.02-1.55) Sex
214/973 European Americans 1.28 (1.03-1.58) Sex
Tomlinson et al. 2007 7,954/6,206 UK CRC pooled 1.21 (1.15-1.27) Crude
620/960 Panel A CRC
White UK residents
1.38 (1.19-1.59) Crude
4,361/3,752 Panel B White UK residents 1.19 (1.12-1.26) Crude
1,901/1,079 Panel C 1.21 (1.09-1.35) Crude
1,072/415 Panel D
European Ancestry
1.13 (0.96-1.33) Crude
1,425/2,255 Adenoma pooled 1.22 (1.10-1.34) Crude
407/1,027 Panel A Adenoma
White UK residents
1.53 (1.29-1.81) Crude
607/765 Panel E 1.05 (0.90-1.23) Crude
411/463 Panel F 1.13 (0.93-1.37) Crude
Poynter et al. 2007 1,339/2,191 USA Population – based 1.11 (0.96-1.29) Age and sex
Tuupanen et al. 2008 996/1,012 Finland Population-based 1.22 (1.08-1.38) Crude
Berndt et al. 2008 3,134/4,454 USA Colorectal neoplasms pooled 1.16 (1.07-1.25) Age, sex, and study
547/1,656 PLCO 1.17 (1.01-1.35) Age and sex
1,174/1,293 PLCO adenoma 1.24 (1.11-1.39) Age and sex
364/363 PLCO II 0.93 (0.75-1.16) Age and sex
544/542 NHS 1.10 (0.93-1.30) Age and sex
505/600 Minnesota 1.21 (1.01-1.44) Age and sex
Ghousaini
et al.
2008 2,299/2,284 UK Cases from prospective
study at East Anglia
1.27 (1.16-1.37) Crude
Lie et al. 2008 561/721 USA Colon cancer cases from
SEER Kentucky
1.69 (1.19-2.40) Age, sex, BMI,
and NSAID use.
Cuacasian 1.61 (1.36-2.30) Age, sex, BMI,
and NSAID use.
Schafmayer 2009 2,713/2,718 Germany Colorectal cancer cases with
German ancestry
1.22 (1.13-1.31) Crude
Curtin et al. 2009 1,069/1,040 USA/UK Colorectal cancer cases from
USA/UK
1.17 (1.03-1.32) Crude
Our study 481/962 Japan HERPACC II participatns (Japanese) 1.22 (1.04-1.44) Age and sex
1.26 (1.06-1.48) Age, sex, drinking,
smoking, BMI, folate
consumption, energy,
physical exercise, and
family history of CRC
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this study may have suffered from information bias:
although the questionnaires were completed before the
diagnosis in our hospital, some patients referred from
other institutions might have known their diagnosis.
Lack of interaction needs careful interpretation because
confounders assessed in this study showed no associa-
tion with CRC risk by themselves.
Conclusion
Our present investigation showed that rs6983267 in
8q24 is an independent risk factor of CRC in a Japanese
population. Further studies to clarify the biological
mechanisms of this association are warranted.
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